USO 25007

MK1022-016: An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy versus Treatment of Physician’s Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

Disease Types: Breast Cancer Research

Eligibility Requirements:

• HR+/HER2- BC LA/MBC
• Centrally-confirmed ER, PR, HER2 and HER3 results from
metastatic site on/after the most recent line of therapy
• PD on 1L CDK4/6i + ET for MBC OR Relapse while on or within 24
months from last dose of adjuvant CDK4/6i + ET
• Pts who received single agent CDK 4/6i or a 2L of ET based tx for
MBC are excluded
• Measurable disease or bone only with lytic/mixed lytic lesions
• Candidate for at least 1 TPC option
• Known germline BRCA mutations are excluded
• Prior chemotherapy for advanced setting is excluded
• Prior tx with an anti-HER3 ab and/or ADC with topo I inhibitor are
excluded.

For more information on this study CLICK HERE .

Available at:

• Chesapeake
• Newport News (Port Warwick III)
• Norfolk (Brock Cancer Center)
• Virginia Beach (Princess Anne)
• Williamsburg